Dermavant raises $200m to ease launch of Otezla rival tapinarofDermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches Share XDermavant raises $200m to ease launch of Otezla rival tapinarofhttps://pharmaphorum.com/news/dermavant-raises-200m-to-ease-launch-of-otezla-rival-tapinarof/
Phase 3 wins put Dermavant closer to filing Otezla rival tapinarofJust two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could Share XPhase 3 wins put Dermavant closer to filing Otezla rival tapinarofhttps://pharmaphorum.com/news/phase-3-wins-put-dermavant-closer-to-filing-otezla-rival-tapinarof/
